Encompass Health Corp

EHC is in a Stage 2 advance within a structural uptrend, but recent price extension above key EMAs and extreme overbought readings warrant patience. We favor pullback-based entries into the rising 9/21 EMA support zone, consistent with a measured Growth at Reasonable Price approach.

• ↑12% YoY revenue growth to $1.46B and 14.9% adjusted EBITDA rise.
• ↑2025 free cash flow guidance $705M–$795M; Q1 share repurchases of $71.6M support returns.
• ↓Uncertain Medicare policy changes could lower reimbursements and compress margins.